141 related articles for article (PubMed ID: 30788155)
1. Low prevalence of deficient mismatch repair (dMMR) protein in locally advanced rectal cancers (LARC) and treatment outcomes.
Ostwal V; Pande NS; Engineer R; Saklani A; deSouza A; Ramadwar M; Sawant S; Mandavkar S; Shrirangwar S; Kataria P; Patil P; Shetty O; Ramaswamy A
J Gastrointest Oncol; 2019 Feb; 10(1):19-29. PubMed ID: 30788155
[TBL] [Abstract][Full Text] [Related]
2. Locally advanced rectal cancer patients with mismatch repair protein deficiency can obtain better pathological response after regional chemoembolization.
Gao Y; Xiao H; Meng W; Liao J; Chen Q; Zhao G; Li C; Bai L
Front Oncol; 2023; 13():1131690. PubMed ID: 37182172
[TBL] [Abstract][Full Text] [Related]
3. The prognostic and predictive value of mismatch repair status in patients with locally advanced rectal cancer following neoadjuvant therapy.
Wu Z; Hu H; Wang C; Zhang J; Cai Y; Xie X; Huang Y; Deng Y
Ann Transl Med; 2022 Apr; 10(8):491. PubMed ID: 35571401
[TBL] [Abstract][Full Text] [Related]
4. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
[TBL] [Abstract][Full Text] [Related]
5. Survival outcomes analysis according to mismatch repair status in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy.
Chen L; Yang X; Zhang Y; Liu J; Jiang Q; Ji F; Gao J; Zhou Z; Wang H; Huang J; Fu C
Front Oncol; 2022; 12():920916. PubMed ID: 36003789
[TBL] [Abstract][Full Text] [Related]
6. Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy.
Cercek A; Dos Santos Fernandes G; Roxburgh CS; Ganesh K; Ng S; Sanchez-Vega F; Yaeger R; Segal NH; Reidy-Lagunes DL; Varghese AM; Markowitz A; Wu C; Szeglin B; Sauvé CG; Salo-Mullen E; Tran C; Patel Z; Krishnan A; Tkachuk K; Nash GM; Guillem J; Paty PB; Shia J; Schultz N; Garcia-Aguilar J; Diaz LA; Goodman K; Saltz LB; Weiser MR; Smith JJ; Stadler ZK
Clin Cancer Res; 2020 Jul; 26(13):3271-3279. PubMed ID: 32144135
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
Zhu J; Ke G; Bi R; Wu X
J Surg Oncol; 2020 Sep; 122(3):538-546. PubMed ID: 32396667
[TBL] [Abstract][Full Text] [Related]
8. [Mismatch repair protein expression of colorectal cancer: a retrospective analysis of 3 428 cases].
Liu Y; Guo YH; Luo Y; Sun L; Zhao S; Shao B; Zang FL; Qiu ZQ; Sun BC; Sun Y
Zhonghua Bing Li Xue Za Zhi; 2021 Apr; 50(4):369-375. PubMed ID: 33831997
[No Abstract] [Full Text] [Related]
9. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
10. Improved Pathologic response to chemoradiation in MGMT methylated locally advanced rectal cancer.
Jensen GL; Pourfarrokh N; Volz M; Morales LL; Walker K; Hammonds KP; El-Ghamry M; Wong L; Hodjat P; Castro E; Rao A; Jhavar SG
Clin Transl Radiat Oncol; 2023 Sep; 42():100667. PubMed ID: 37560324
[TBL] [Abstract][Full Text] [Related]
11. Mismatch repair system deficiency is associated with chemoradiotherapy resistance in locally advanced rectal adenocarcinoma patients.
Ni K; Zhan Y; Liu Z; Zhao XZ; Wang W; Wang G; Zhang Z; Li G; Zhang X; Zhang C
J Surg Oncol; 2022 Mar; 125(4):692-702. PubMed ID: 34918842
[TBL] [Abstract][Full Text] [Related]
12. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched.
Tsai CY; Lin TA; Huang SC; Hsu JT; Yeh CN; Chen TC; Chiu CT; Chen JS; Yeh TS
Oncologist; 2020 Jul; 25(7):e1021-e1030. PubMed ID: 32058649
[TBL] [Abstract][Full Text] [Related]
13. Pathological complete response in MMR-deficient/MSI-high and KRAS-mutant patient with locally advanced rectal cancer after neoadjuvant chemoradiation with immunotherapy: A case report.
Zhang M; Yang H; Chen L; Du K; Zhao L; Wei L
Front Oncol; 2022; 12():926480. PubMed ID: 36212424
[TBL] [Abstract][Full Text] [Related]
14. Pathologic Outcomes of Short-Course and Long-Course Radiotherapy for Locally Advanced Rectal Cancers Treated With Total Neoadjuvant Therapy.
Williams B; Gupta A; Iype P; Woll S; Koller SE; Shin J; Cologne KG; Lee SW; Duldulao MP
Am Surg; 2024 May; ():31348241256055. PubMed ID: 38770756
[TBL] [Abstract][Full Text] [Related]
15. Endometrial Cancer Presentation and Outcomes Based on Mismatch Repair Protein Expression From a Population-Based Study.
Pina A; Wolber R; McAlpine JN; Gilks B; Kwon JS
Int J Gynecol Cancer; 2018 Oct; 28(8):1624-1630. PubMed ID: 30095707
[TBL] [Abstract][Full Text] [Related]
16. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer.
Seo I; Lee HW; Byun SJ; Park JY; Min H; Lee SH; Lee JS; Kim S; Bae SU
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33692216
[TBL] [Abstract][Full Text] [Related]
18. Long-term Oncologic Outcomes After Neoadjuvant Chemoradiation Followed by Intersphincteric Resection With Coloanal Anastomosis for Locally Advanced Low Rectal Cancer.
Park JS; Park SY; Kim HJ; Cho SH; Kwak SG; Choi GS
Dis Colon Rectum; 2019 Apr; 62(4):408-416. PubMed ID: 30688680
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of the relationship of DNA mismatch repair with clinicopathologic features and prognosis of colon cancer].
Qin Q; Ying J; Lyu N; Guo L; Zhi W; Zhou A; Wang J
Zhonghua Zhong Liu Za Zhi; 2015 Aug; 37(8):591-6. PubMed ID: 26714599
[TBL] [Abstract][Full Text] [Related]
20. Deciding the operation type according to mismatch repair status among hereditary nonpolyposis colorectal cancer patients: should a tailored approach be applied, or does one size fit all?
Liao CK; Lin YC; Hsu YJ; Chern YJ; You JF; Chiang JM
Hered Cancer Clin Pract; 2021 Jun; 19(1):29. PubMed ID: 34187536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
